Diagnosis of allograft dysfunction by noninvasive biomarker tests is preferable to invasive allograft biopsies and has been extensively considered in recent years. This study aims to evaluate blood and urinary forkhead box P3 (FOXP3) messenger RNA (mRNA) expression in renal transplant recipients in an attempt to determine whether differential diagnosis of graft dysfunction is feasible using mRNA profiles.
Methods:
We analyzed FOXP3 mRNA expression in paired urinary and peripheral blood mononuclear cell (PBMC) samples. A total of 91 kidney transplant recipients enrolled in this study that were classified into 3 groups: biopsy-proven acute rejection (AR; n = 27), chronic allograft nephropathy (n = 19), and well-functioning graft (n = 45). The FOXP3 mRNA expression was quantified by TaqMan probe real-time polymerase chain reaction.
Results:
Acute rejection patients had a higher expression level of transcription factor FOXP3 compared to the chronic nephropathy and control groups. Analysis of receiver operating characteristic curves showed that rejection could be diagnosed with 100% sensitivity and 96% specificity in urine, and 92% sensitivity and 86% specificity in PBMC samples using the optimal FOXP3 mRNA cutoff value. We subdivided the AR group into progressive and nonprogressive patients, which showed a significant difference in FOXP3 mRNA expression. This result confirmed the role of FOXP3 as a diagnostic marker in predicting transplantation outcomes.
Conclusion:
Our results suggested that elevated expression of FOXP3 in blood and urine samples from kidney transplant recipients could be a useful noninvasive biomarker to diagnose graft dysfunction.
SolezKColvinRBRacusenLC. Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant. 2007;7(3):518–526.
2.
GastonRSCeckaJMKasiskeBL. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90(1):68–74. doi:10.1097/TP.0b013e3181e065de.
3.
SellaresJde FreitasDGMengelM. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388–399. doi:10.1111/j.1600-6143.2011.03840.x.
4.
RobertsDMJiangSHChadbanSJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94(8):775–783. doi:10.1097/TP.0b013e31825d1587.
5.
WiesnerRHFungJJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 2011;17(suppl 3): S1–S9. doi:10.1002/lt.22410.
6.
RosboroughBRRaïch-ReguéDLiuQVenkataramananRTurnquistHRThomsonAW. Adenosine triphosphate-competitive mTOR Inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014;14(9):2173–2180. doi:10.1111/ajt.12799.
7.
ReeveJSellarésJMengelM. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant. 2013;13(3):645–655. doi:10.1111/ajt.12079.
8.
HaasM. Donor kidney biopsies: pathology matters, and so does the pathologist. Kidney Int. 2014;85(5):1016–1019. doi:10.1038/ki.2013.439.
9.
MaoYWangMZhouQ. CXCL10 and CXCL13 expression were highly up-regulated in peripheral blood mononuclear cells in acute rejection and poor response to anti-rejection therapy. J Clin Immunol. 2011;31(3):414–418. doi:10.1007/s10875-010-9500-8.
IwaseHKobayashiTKoderaY. Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation. Transplantation. 2011;91(2):191–198. doi:10.1097/TP.0b013e3181ffbab4.
13.
SuthanthiranMSchwartzJEDingR. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013;369(1):20–31. doi:10.1056/NEJMoa1215555.
14.
FrancisRSFengGTha-InTLyonsISWoodKJBushellA. Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol. 2011;41(3):726–738. doi:10.1002/eji.201040509.
15.
FanZSpencerJALuY. In vivo tracking of ‘color-coded’ effector, natural and induced regulatory T cells in the allograft response. Nat Med. 2010;16(6):718–722. doi:10.1038/nm.2155.
16.
DummerCDCarpioVNGonçalvesLFManfroRCVeroneseFV. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl Immunol. 2012;26(1):1–10. doi:10.1016/j.trim.2011.08.009.
17.
HoriSNomuraTSakaguchiS. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061.
18.
RamsdellFZieglerSF. FOXP3 and scurfy: how it all began. Nat Rev Immunol. 2014;14(5):343–349. doi:10.1038/nri3650.
19.
HarbuzRLespinasseJBouletS. Identification of new FOXP3 mutations and prenatal diagnosis of IPEX syndrome. Prenat Diagn. 2010;30(11):1072–1078. doi:10.1002/pd.2613.
20.
BacchettaRBarzaghiFRoncaroloMG. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation [published online ahead of print]. Ann N Y Acad Sci. 2016. doi:10.1111/nyas.13011.
21.
MoesNRieux–LaucatFBegueB. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology. 2010;139(3):770–778. doi:10.1053/j.gastro.2010.06.006.
22.
KangSMTangQBluestoneJA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. AmJ Transplant. 2007;7(6):1457–1463.
23.
YongZChangLMeiYXYiL. Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl Immunol. 2007;17(2):120–129.
24.
BatsfordSDickenmannMDurmullerUHopferHGudatFMihatschM. Is monitoring of FOXP3 Treg cells in renal transplants during acute cellular rejection episodes useful?Clin Nephrol. 2011;75(2):101–106.
25.
BeierUHWangLBhattiTR. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol. 2011;31(5):1022–1029. doi:10.1128/MCB.01206-10.
26.
BhoradeSMChenHMolineroL. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation. 2010;90(5):540–546. doi:10.1097/TP.0b013e3181e8dab.
27.
HeQFanHLiJQQiHZ. Decreased circulating CD4+CD25high Foxp3+ T cells during acute rejection in liver transplant patients. Transplant Proc. 2011;43(5):1696–1700. doi:10.1016/j.transproceed.2011.03.084.
28.
TurnquistHRZhaoZRosboroughBR. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol. 2011;187(9):4598–4610. doi:10.4049/jimmunol.1100519.
29.
NikoueinejadHAmirzargarASarrafnejadA. Dynamic changes of regulatory T cell and dendritic cell subsets in stable kidney transplant patients: a prospective analysis. Iran J Kidney Dis. 2014;8(2):130–138.
30.
KarczewskiMKarczewskiJKostrzewaAWiktorowiczKGlydaM. The role of Foxp3+ regulatory T cells in kidney transplantation. Transplant Proc. 2009;41(5):1527–1529. doi:10.1016/j.transproceed.2009.03.065.
31.
KollinsDStoelckerBHoffmannU. FOXP3+ regulatory T-cells in renal allografts: correlation with long-term graft function and acute rejection. Clin Nephrol. 2011;75(2):91–100.
32.
MuthukumarTDadhaniaDDingR. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. New Engl J Med. 2005;353(22):2342–2351.
33.
NazariBAmirzargarANikbinB. Comparison of the Th1, IFN-gamma secreting cells and FoxP3 expression between patients with stable graft function and acute rejection post kidney transplantation. Iran J Allergy Asthma Immunol. 2013;12(3):262–268.
34.
Abd ElazizMMBakrySM Abd ElAalAERashedLHeshamD. Validation of Urinary PD-1 and FOXP3 mRNA in a cohort of Egyptian renal allograft recipients. Ann Transplant. 2016;21:17–24.
35.
DijkeIEWeimarWBaanCC. Regulatory T cells after organ transplantation: where does their action take place?Hum Immunol. 2008;69(7):389–398. doi:10.1016/j.humimm.2008.05.006.
36.
BestardOCruzadoJMRamaI. Presence of FoxP3+ regulatory T cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol. 2008;19(10):2020–2026. doi:10.1681/ASN.2007111174.
37.
YapiciUBemelmanFJScheepstraCG. Intragraft FOXP3 protein or mRNA during acute renal allograft rejection correlates with inflammation, fibrosis, and poor renal outcome. Transplantation. 2009;87(9):1377–1380. doi:10.1097/TP.0b013e3181a24a4b.
38.
BunnagSAllanachKJhangriGS. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant. 2008;8(7):1423–1433. doi:10.1111/j.1600-6143.2008.02268.x.
39.
ZuberJGrimbertPBlanchoG. Prognostic significance of graft Foxp3 expression in renal transplant recipients: a critical review and attempt to reconcile discrepancies. Nephrol Dial Transplant. 2013;28(5):1100–1111. doi:10.1093/ndt/gfs570.
40.
VeroneseFRotmanSSmithRN. Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. AmJ Transplant. 2007;7(4):914–922.
41.
AssadiaslSAhmadpoorPNafarM. Regulatory T cell subtypes and TGF-beta1 gene expression in chronic allograft dysfunction. Iran J Immunol. 2014;11(3):139–152. doi:IJIv11i3A1.
42.
DerveauxSVandesompeleJHellemansJ. How to do successful gene expression analysis using real-time PCR. Methods. 2010;50(4):227–230. doi:10.1016/j.ymeth.2009.11.001.
43.
BestardOCunettiLCruzadoJM. Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and are protective biomarkers for kidney graft outcome. Am J Transplant. 2011;11(10):2162–2172. doi:10.1111/j.1600-6143.2011.03633.x.
